Table 1 Descriptive characteristics
|  | 18–44 years | 45–70 years | ||
|---|---|---|---|---|
Control group | Three-dose group | Control group | Three-dose group | |
N = 218,591 | N = 218,591 | N = 97,059 | N = 97,059 | |
Female, N (%) | 94,362 (43.2%) | 94,362 (43.2%) | 43,630 (45.0%) | 43,630 (45.0%) |
Norwegian, N (%) | 180,356 (82.5%) | 180,356 (82.5%) | 71,918 (74.1%) | 71,918 (74.1%) |
Age, mean (SD) | 30.2 (7.8) | 30.2 (7.8) | 54.4 (6.8) | 54.4 (6.8) |
Education, N (%) | ||||
 No or missing | 10,437 (4.8%) | 10,437 (4.8%) | 2867 (3.0%) | 2867 (3.0%) |
 Primary school | 48,367 (22.1%) | 48,367 (22.1%) | 18,231 (18.8%) | 18,231 (18.8%) |
 Upper sec. school | 76,755 (35.1%) | 76,755 (35.1%) | 42,110 (43.4%) | 42,110 (43.4%) |
 1 > year university/college | 83,032 (38.0%) | 83,032 (38.0%) | 33,851 (34.9%) | 33,851 (34.9%) |
Comorbidities | ||||
 0 | 212,114 (97.0%) | 212,114 (97.0%) | 84,690 (87.3%) | 84,690 (87.3%) |
 1 | 6448 (2.9%) | 6448 (2.9%) | 11,287 (11.6%) | 11,287 (11.6%) |
 2 | 29 (0.0%) | 29 (0.0%) | 1027 (1.1%) | 1027 (1.1%) |
  ≥ 3 | 0 | 0 | 55 (0.1%) | 55 (0.1%) |
All-cause PC visits, N (%) | ||||
 0 | 30,000 (13.7%) | 30,000 (13.7%) | 15,123 (15.6%) | 15,123 (15.6%) |
 1 | 26,973 (12.3%) | 26,973 (12.3%) | 10,999 (11.3%) | 10,999 (11.3%) |
 2–4 | 71,521 (32.7%) | 71,521 (32.7%) | 28,627 (29.5%) | 28,627 (29.5%) |
 5–9 | 58,426 (26.7%) | 58,426 (26.7%) | 25,223 (26.0) | 25,223 (26.0) |
  ≥ 10 | 31,671 (14.5%) | 31,671 (14.5%) | 17,087 (17.6%) | 17,087 (17.6%) |
Hospital admissions, N (%) | ||||
 0 | 207,723 (95.0%) | 207,723 (95.0%) | 94,228 (97.1%) | 94,228 (97.1%) |
 1 | 10,393 (4.8%) | 10,393 (4.8%) | 2694(2.8%) | 2694(2.8%) |
 2 | 443 (0.2%) | 443 (0.2%) | 126 (0.1%) | 126 (0.1%) |
  ≥ 3 | 32 (0.0%) | 32 (0.0%) | 11 (0.0%) | 11 (0.0%) |
Negative tests, N (%) | ||||
 0 | 162,056 (74.1%) | 162,056 (74.1%) | 84,459 (87.0%) | 84,459 (87.0%) |
 1 | 40,773 (18.7%) | 40,773 (18.7%) | 10,193 (10.5%) | 10,193 (10.5%) |
 2 | 11,269 (5.2%) | 11,269 (5.2%) | 1806 (1.9%) | 1806 (1.9%) |
  ≥ 3 | 4493 (2.1%) | 4493 (2.1%) | 601 (0.6%) | 602 (0.6%) |
Previously positive, N (%) | 5 (0.0%) | 5 (0.0%) |  > 5 (0.0%)a |  > 5 (0.0%)a |
Days since 2nd dose, (SD) | 148.7 (15.4) | 149.0 (15.2) | 158.4 (22.1) | 158.7 (21.8) |